Context Low-risk differentiated thyroid cancer (DTC) is overdiagnosed, but true incidence
has increased as well. Owing to its excellent prognosis with low morbidity and mortality …

Thyroid nodules have garnered attention due to changes in population surveillance systems
and rising concerns about the associated financial burden on healthcare systems, payers …

Thyroid cancer is the most common endocrine malignancy with an estimated 43,800 new
cases to be diagnosed in 2022 and representing the 7th most common cancer in women …

Purpose This review focuses on post-operative thyroid hormone replacement and
thyrotropin suppression therapy in patients with differentiated thyroid cancer. Methods A …

Objective To determine the frequency of levothyroxine (LT4) supplementation after
therapeutic lobectomy for low-risk differentiated thyroid cancer (DTC). Methods This …

Thyroid cancer incidence is on the rise; however, fortunately, the death rate is stable. Most
persons with well-differentiated thyroid cancer have a low risk of recurrence at the time of …

Background After thyroidectomy some patients experience a chronic fatigue syndrome
called asthenia. The purpose of this study was to determine the post-operative health related …

Background The decision to pursue lobectomy versus total thyroidectomy is highly
individualized. The rate of thyroid hormone replacement therapy after lobectomy varies …

Abstract Context The 2015 American Thyroid Association guidelines proposed thyroid
lobectomy as an acceptable option for 1-to 4-cm papillary thyroid cancers (PTC) without …

Senescence-induced therapy was previously considered as an effective treatment for
tumors, and cellular senescence was initially regarded as an effective mechanism against …